Bas P. H. Adriaansen

Bas P. H. Adriaansen

Auto-generated profile, based on publicly available information

Bas P. H. Adriaansen

Department of Pediatrics, Division of Pediatric Endocrinology, Amalia Children's Hospital, Radboud University Medical Center , Nijmegen 6500HB

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
BABas P. H. Adriaansen
Bas P. H. Adriaansen
JKJohannes S. Kamphuis
Johannes S. Kamphuis
MSMariska A. M. Schröder
Mariska A. M. Schröder
AOAndré J. Olthaar
André J. Olthaar
CBCarina Bock
Carina Bock
AHAntonius E. van Herwaarden
Antonius E. van Herwaarden
Objective: Treatment of congenital adrenal hyperplasia (CAH) patients with glucocorticoids is often challenging since there is a delicate balance between over‐ and undertreatment. Treatment can be monitored noninvasively by measuring salivary androstenedione (A4) and 17‐hydroxyprogesterone (17‐OHP). Optimal treatment monitoring requires the establishment of reference values in saliva.Design: A descriptive study.Patients: For this study saliva of 255 healthy paediatric and adult volunteers with an age range of 4–75 years old was used.Measurements: We developed a sensitive liquid chromatography‐tandem mass spectrometry method, assessed salivary A4 and 17‐OHP stability, and measured A4 and 17‐OHP concentrations in saliva collected in the morning, afternoon, and evening.Results: We quantified A4 and 17‐OHP concentrations in the morning, afternoon, and evening and demonstrated that there is a significant rhythm with the highest levels in the morning and decreasing levels over the day. A4 and 17‐OHP concentrations display an age‐dependent pattern. These steroids remain stable in saliva at ambient temperature for up to 5 days.Conclusions: Good stability of the steroids in saliva enables saliva collection by the patient at home. Since salivary A4 and 17‐OHP display a diurnal rhythm and age‐dependent pattern, we established reference values for both children and adults at three time points during the day. These reference values support treatment monitoring of children and adults with CAH.

21 January 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
HGHedi L Claahsen-Van der Grinten
Hedi L Claahsen-Van der Grinten
BABas P H Adriaansen
Bas P H Adriaansen
Henrik FalhammarHenrik Falhammar
Henrik Falhammar
Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency results in severe cortisol and aldosterone deficiency, leading to persistent adrenal stimulation and excess production of ACTH and adrenal androgens. This review examines the clinical considerations and challenges of balancing under- and overtreatment with glucocorticoids in adolescent and adult male individuals with CAH. Adolescents face many unique challenges that can hinder adherence, hormonal control, and transition to independence. Thus, patient education is critical during adolescence, especially in poorly controlled postpubertal males who lack obvious symptoms and may not recognize the long-term consequences of nonadherence, such as reduced final height, reduced reproductive health, poor bone health, obesity, and hypertension. The risk of subfertility/infertility begins early, especially in males with poor hormonal control, who often have reduced sperm counts, small testes, and benign tumors called testicular adrenal rest tumors (TARTs). Even males with good hormonal control can experience subfertility/infertility due to TARTs. In addition, several factors such as hypogonadism and long-term glucocorticoid treatment can predispose males with CAH to poor bone health (eg, low bone mineral density, increased risk of osteoporosis/osteopenia and fractures) and metabolic syndrome (eg, obesity, insulin resistance, dyslipidemia, and hypertension). Regular monitoring is recommended, with glucocorticoid dose optimization and prophylactic treatment to maximize future fertility potential and protect long-term bone health. Early implementation of lifestyle interventions and medical treatment are needed to address cardiometabolic consequences.

3 January 2024 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
BABas P H Adriaansen
Bas P H Adriaansen
SASandra E Oude Alink
Sandra E Oude Alink
DSDorine W Swinkels
Dorine W Swinkels
MSMariska A M Schröder
Mariska A M Schröder
Paul SpanPaul Span
Paul Span
AHAntonius E van Herwaarden
Antonius E van Herwaarden
Classic androgens such as dehydroepiandrosterone, androstenedione, and testosterone are generally measured for diagnosis and treatment monitoring in children and adolescents with hyperandrogenism, as can occur in congenital adrenal hyperplasia, premature pubarche, or polycystic ovarian syndrome. However, adrenally-derived 11-oxygenated androgens also contribute to the androgen pool and should therefore be considered in clinical management. Nevertheless, paediatric reference intervals are lacking. Therefore, we developed a serum assay to establish reference intervals for four 11-oxygenated androgens in addition to four classic androgens. Reference interval study for serum 11-oxygenated androgens in children. We developed and validated a sensitive liquid chromatography-tandem mass spectrometry assay and quantified eight serum androgens, including four 11-oxygenated androgens, in serum of 256 healthy children (aged 0-17 years old). An age-dependency for all androgens was observed, and therefore we divided the cohort based on age (prepubertal [n = 133; 94 boys, 39 girls] and pubertal [n = 123; 52 boys, 71 girls]) to compute reference intervals (2.5th-97.5th percentiles). In the prepubertal group, there was no significant sex-difference for any of the measured androgens. In the pubertal group, androstenedione, testosterone, and dihydrotestosterone showed a significant difference between boys and girls. In contrast, adrenal androgens dehydroepiandrosterone, 11-hydroxyandrostenedione, 11-ketoandrostenedione, 11-hydroxytestosterone, and 11-ketotestosterone did not. We developed and validated an assay for 11-oxygenated androgens, in addition to four classic androgens and established reference intervals. This enables a comprehensive evaluation of serum androgen status in children with clinical symptoms of hyperandrogenism.

14 October 2023 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
MSMariska A M Schröder
Mariska A M Schröder
MNMihaela Neacşu
Mihaela Neacşu
BABas P H Adriaansen
Bas P H Adriaansen
FSFred C G J Sweep
Fred C G J Sweep
SAS Faisal Ahmed
S Faisal Ahmed
HGHedi L Claahsen-Van der Grinten
Hedi L Claahsen-Van der Grinten
Importance: Testicular adrenal rest tumors (TARTs), often found in male patients with congenital adrenal hyperplasia (CAH), are benign lesions causing testicular damage and infertility. We hypothesize that chronically elevated adrenocorticotropic hormone exposure during early life may promote TART development. Objective: This study aimed to examine the association between commencing adequate glucocorticoid treatment early after birth and TART development. Design and participants: This retrospective multicenter (n = 22) open cohort study collected longitudinal clinical and biochemical data of the first 4 years of life using the I-CAH registry and included 188 male patients (median age 13 years; interquartile range: 10-17) with 21-hydroxylase deficiency (n = 181) or 11-hydroxylase deficiency (n = 7). All patients underwent at least 1 testicular ultrasound. Results: TART was detected in 72 (38%) of the patients. Prevalence varied between centers. When adjusted for CAH phenotype, a delayed CAH diagnosis of >1 year, compared with a diagnosis within 1 month of life, was associated with a 2.6 times higher risk of TART diagnosis. TART onset was not predicted by biochemical disease control or bone age advancement in the first 4 years of life, but increased height standard deviation scores at the end of the 4-year study period were associated with a 27% higher risk of TART diagnosis. Conclusions and relevance: A delayed CAH diagnosis of >1 year vs CAH diagnosis within 1 month after birth was associated with a higher risk of TART development, which may be attributed to poor disease control in early life.

26 August 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
BABas P H Adriaansen
Bas P H Adriaansen
Agustini UtariAgustini Utari
Agustini Utari
AOAndré J Olthaar
André J Olthaar
RSRob C B M van der Steen
Rob C B M van der Steen
KPKarijn J Pijnenburg-Kleizen
Karijn J Pijnenburg-Kleizen
AHAntonius E van Herwaarden
Antonius E van Herwaarden
Context Some patients with classic congenital adrenal hyperplasia (CAH) survive without glucocorticoid treatment. Increased precursor concentrations in these patients might lead to higher free (biological active) cortisol concentrations by influencing the cortisol-protein binding. In 21-hydroxylase deficiency (21OHD), the most common CAH form, accumulated 21-deoxycortisol (21DF) may further increase glucocorticoid activity. Both mechanisms could explain the low occurrence of symptoms in some untreated classic CAH patients. Objective Develop and validate an LC-MS/MS method for free cortisol and free 21DF to quantify these steroids in untreated patients with classic CAH (n=29), non-classic CAH (NCCAH, n=5), other forms of adrenal insufficiency (AI, n=3), and controls (n=11) before and 60 minutes after Synacthen® administration. Results Unstimulated total cortisol concentrations of untreated classic CAH patients (median 109 nmol/L) were lower than in untreated NCCAH patients (249 nmol/L, p=0.010) and controls (202 nmol/L, p=0.016), but free cortisol concentrations were similar. Basal free 21DF concentrations were high in 21OHD patients (median 5.32 nmol/L) and undetectable in AI patients and controls (<0.19 nmol/L). After Synacthen® administration, free 21DF concentrations increased in 21OHD patients, while free cortisol concentrations did not change. Conclusions Free cortisol concentrations in classic CAH patients were similar to those in controls and NCCAH patients, indicating comparable cortisol availability. Additionally, 21OHD patients produce high concentrations of 21DF, possibly explaining the low occurrence of symptoms in some classic 21OHD patients. Free cortisol and 21DF levels should be considered in evaluating adrenal insufficiency in patients with CAH.

29 September 2023 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
PDF file
BABas P.H. Adriaansen
Bas P.H. Adriaansen
AHAntonius E. van Herwaarden
Antonius E. van Herwaarden
FSFred C.G.J. Sweep
Fred C.G.J. Sweep
HGHedi L. Claahsen-Van der Grinten
Hedi L. Claahsen-Van der Grinten
We have read the paper “Compromised adult height in females with non-classical congenital adrenal hyperplasia diagnosed in childhood” by R. Bello, L. Lazar, M. Phillip, and L. de Vries [1] with great interest. Although reduced final height is a common consequence in adults with classic congenital adrenal hyperplasia (CAH), final height data in untreated non-classic CAH (NCCAH) are scarce, and the effect of glucocorticoid treatment to improve final height is still under debate [2]. Therefore, studies evaluating the natural course of height in patients with NCCAH can add important knowledge.In this article, the authors present data on a large group of females with NCCAH who reached their final height. They showed that the final height was significantly below the target height in this group. Based on their findings, the authors suggest that the androgen excess in these patients, rather than the glucocorticoid treatment, is the main cause of the compromised adult height. We question whether the methodology of this study is sufficient to draw this conclusion as confounding bias could have interfered with the study results, and therefore we would like to make some contributions.In this study, the diagnosis was not genetically confirmed in 27% of the patients. Therefore, inclusion of more severe forms of CAH, such as simple virilizing CAH, cannot be ruled out, especially in those patients with strongly elevated 17OHP levels. A more severe genotype can also be considered in those patients who developed symptoms at a very young age. The high prevalence of central precocious puberty (CPP) and early puberty (EP) also suggests the possible inclusion of patients with a more severe genotype. Moreover, the presence of CPP or EP in these patients might contribute to a decreased adult height [3], irrespective of the NCCAH itself. A statistical approach to correct for the disease severity or presence of CPP/EP could help draw more robust conclusions.Furthermore, the authors included patients from 1986 to 2017. During this period, treatment recommendations changed significantly, resulting in heterogeneity of the treatment. In addition, no results are presented on follow-up and treatment compliance. Interestingly, 17 patients were never treated with glucocorticoids. In these patients, the final height would be of special interest. It could be valuable to describe them separately to gain knowledge about the natural course of NCCAH.Further studies, including prospective controlled studies, are necessary to study the effects of glucocorticoids on final height in NCCAH in more detail. As these studies are hard to perform, retrospective studies can be done, but it is important to homogenize the group as much as possible or to correct for bias in the statistical approach.The authors have no conflicts of interest to declare.The authors declare that no financial support was received.All authors contributed substantially to the work, critically reviewed the content, gave final approval for publication, and are accountable for all aspects of the work.